Enliven Therapeutics Files 8-K: Material Agreement & Equity Sales
Ticker: ELVN · Form: 8-K · Filed: Mar 19, 2024 · CIK: 1672619
| Field | Detail |
|---|---|
| Company | Enliven Therapeutics, Inc. (ELVN) |
| Form Type | 8-K |
| Filed Date | Mar 19, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $14.00, $13.999, $90 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, regulation-fd
TL;DR
Enliven Therapeutics (ENLV) filed an 8-K on 3/19, reporting a material agreement and equity sales.
AI Summary
Enliven Therapeutics, Inc. announced on March 19, 2024, that it entered into a Material Definitive Agreement. The company also disclosed unregistered sales of equity securities and provided Regulation FD disclosures. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity, including a material definitive agreement and unregistered equity sales, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Enliven Therapeutics, Inc. (company) — Registrant
- March 19, 2024 (date) — Date of Report
- 001-39247 (company) — SEC File Number
- 6200 Lookout Road, Boulder, Colorado 80301 (location) — Principal Executive Offices
- 720 647-8519 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the Material Definitive Agreement?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on or before March 19, 2024.
What type of equity securities were sold in the unregistered sale?
The filing mentions unregistered sales of equity securities but does not specify the type or amount of securities sold.
When was Enliven Therapeutics, Inc. incorporated?
Enliven Therapeutics, Inc. was incorporated in Delaware.
What is the company's former name?
The company's former name was IMARA Inc., with a date of name change on April 19, 2016.
What is the company's SIC code?
The company's Standard Industrial Classification (SIC) code is 2834, Pharmaceutical Preparations.
Filing Stats: 1,514 words · 6 min read · ~5 pages · Grade level 13.5 · Accepted 2024-03-19 08:46:02
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ELVN The Nasdaq Global Se
- $14.00 — .001 per share (the "Common Stock"), at $14.00 per Share, and (ii) pre-funded warrants
- $13.999 — e "Securities"), at a purchase price of $13.999 per Pre-Funded Warrant. The Pre-Funde
- $90 m — Private Placement will be approximately $90 million, before deducting offering expens
Filing Documents
- d759882d8k.htm (8-K) — 36KB
- d759882dex41.htm (EX-4.1) — 70KB
- d759882dex101.htm (EX-10.1) — 233KB
- d759882dex991.htm (EX-99.1) — 29KB
- g759882g0319113839095.jpg (GRAPHIC) — 5KB
- 0001193125-24-070839.txt ( ) — 600KB
- elvn-20240319.xsd (EX-101.SCH) — 3KB
- elvn-20240319_lab.xml (EX-101.LAB) — 18KB
- elvn-20240319_pre.xml (EX-101.PRE) — 11KB
- d759882d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements Page 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Enliven Therapeutics, Inc. Date: March 19, 2024 By: /s/ Samuel Kintz Name: Samuel Kintz Title: President and Chief Executive Officer Page 4